Antabio is a private European biopharmaceutical company developing novel and highly differentiated antibacterial treatments for WHO critical priority pathogens with a particular focus on life-threatening respiratory infections.

The company’s portfolio includes ANT3310 which addresses drug-resistant hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and the PEi program which is focused on chronic lung infections caused by Pseudomonas aeruginosa in CF patients. A third program, ANT2681, targets NDM-producing carbapenem-resistant Enterobacterales (CRE).

Antabio has built an international team with highly successful track records, including former executives/Manager from Novexel, Merck, GSK and Astra Zeneca.

The company has raised over €23m in non-dilutive financing to date from Wellcome Trust (2 SDD awards, 2013 and 2015) and CARB-X (2017). The company also completed a €12,5m series A round in 2017 with second closing in 2018.


Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium

Marc Lemonnier – CEO, Antabio